Eledon Pharmaceuticals ( (ELDN) ) has shared an update.
Eledon Pharmaceuticals announced an $85 million underwritten offering of common stock and pre-funded warrants, with the proceeds intended to advance its pipeline and general corporate purposes. The offering, priced at $3.65 per share for common stock and $3.649 for pre-funded warrants, is expected to close by October 30, 2024, subject to customary conditions. This initiative aims to further Eledon’s development of immune-modulating therapies, including its lead product, tegoprubart, targeting life-threatening conditions.
See more insights into ELDN stock on TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
